Category Archives: Science

Enabling microRNA Discoveries – 250th Peer-Reviewed Publication Made Possible By µparaflo Custom Microarray Technology

Jun 09 2011 /RTPR/ – LC Sciences, a life sciences company leading the development of innovative microRNA (miRNA) analysis and discovery technologies, announced today the publication of over 250 peer-reviewed studies using the company’s microarray service for analyzing miRNA expression profiles. These studies, by leading researchers in the field, represent significant steps toward realizing these small regulatory RNA’s potential as biomarkers and therapeutic targets.

MiRNAs have proven to be an extremely important part of the gene expression regulation mechanism of a wide variety of cellular processes. This is evident in the amount of relevant findings by LC Sciences’ customers being translated into published reports and the diverse range of study areas that these publications encompass: cancer research, neuroscience, cardiovascular research, reproductive biology, plant science, microbiology, immunology and stem cell research. LC Sciences’ miRNA profiling service, powered by its µParaflo® custom microarray technology, provides quick, reliable, fully analyzed datasets enabling researchers to immediately move forward with groundbreaking research.

The miRNA field is still nascent, and it is advancing rapidly. The race to discovery has produced a continuous stream of new miRNA sequences as well as routine revisions of inaccurate or incomplete sequences. This fluidity has caused many microarrays with static content to fall away and has fueled reports of the wholesale replacement of microarrays by new methods such as RNA-Seq. But the nimble, customizable format of the µParaflo® array has given it staying power, not only by enabling it to keep current with all known miRNAs, but also by making use of data generated by RNA-Seq. These custom arrays have benefited from RNA-sequencing generating novel content that other arrays are unable to capture and take advantage of.

The 250th study, entitled “Wolbachia uses host microRNAs to manipulate host gene expression and facilitate colonization of the dengue vector Aedes aegypti.” appeared in the May 31st issue of PNAS and was one of a group of articles published recently by LC Sciences’ customers describing microarray expression analysis of miRNAs recently discovered through RNA Sequencing.

Researchers at the University of Queensland, Australia studied the underlying mechanisms of host manipulation by a widespread endosymbiont. Using microarrays, they show that the miRNA profile of the mosquito, Aedes aegypti, is significantly altered by a life-shortening strain of W. pipientis bacteria. This is extremely important work as introduction of Wolbachia into mosquitoes has been proposed as a method for malaria control. They found that a host miRNA (aae-miR-2940) is induced after W. pipientis infection in both mosquitoes and cell lines.

This study illustrates the versatility of µParaflo® from a couple of perspectives. First, mosquito, an important though non-model species was the target of interest here and mosquito arrays, as well as arrays from any of the 153 species listed in the miRBase public sequence database, are readily available from LC Sciences. Second, custom content (novel miRNA sequences from an earlier sequencing study on the same species) was quickly integrated into the content of the insect array providing an even richer expression dataset. Though all the previously described, known insect miRNAs were also present on the arrays, several custom sequences were significantly differentially expressed in infected mosquitoes and a custom sequence turned out to be one that became a focus of the investigation. Dr. Sassan Asgari, lead researcher for the study, commented that microarrays “…provided an affordable approach to the study of differential expression of small RNAs and miRNAs in particular.”

“We are very excited about the announcement of the 250th peer-viewed publication by one of our microarray customers,” says Chris Hebel, VP of Business Development at LC Sciences. “We were the first to provide a microarray expression profiling service for miRNA back in 2005 and proud to be still going strong in the face of rapidly advancing technologies, while many other less adaptable arrays, have fallen away. Despite the apparent advantages of new technologies such as RNA-Seq, microarrays have been the gene expression workhorse for many years and continue to be a robust, affordable solution. High-throughput RNA sequencing is still significantly more expensive and it won’t be until there is sufficient multiplexing of samples when we finally do reach a cost approaching that of microarrays. Of course more samples means less coverage per sample, and I think we’re still trying to figure out just how much coverage is required for robust expression data from deep sequencing and therefore what level of multiplexing can ultimately be reached. Meanwhile, RNA-Seq has become an amazing tool for discovery of novel miRNAs and continues to provide new content for our custom microarrays.”

About µParaflo® Technology – The µParaflo® technology is a microfluidic platform for in situ parallel synthesis of biomolecular chips and miniaturization of bioassays including hybridization, binding and enzymatic reactions. This unique platform technology is based on pico-liter microfluidic reaction devices and a digital light controlled synthesis method that employs conventional oligonucleotide or peptide synthesis chemistry; a completely programmable process. The seamless integration of these multidisciplinary technologies enables a significant advance in
parallelization, miniaturization, customization, and automation.

About LC Sciences – LC Sciences offers discovery, profiling and validation services for microRNA and other small RNAs. Services include deep sequencing for discovery applications, microarrays for differential expression profiling and validation/confirmation of newly discovered microRNAs, and qRT-PCR for quantitation of microRNA expression levels. These comprehensive services are designed to be one-stop and produce the results needed to quickly advance your biological and biomedical research. Combining the latest deep sequencing technology with ourµParaflo® on chip synthesis technology offers unprecedented flexibility and customization capability.

More information about LC Sciences is available at www.lcsciences.com.

Hussain M, Frentiu FD, Moreira LA, O’Neill SL, Asgari S. (2011) Wolbachia uses host microRNAs to manipulate host gene expression and facilitate colonization of the dengue vector Aedes aegypti. Proc Natl Acad Sci USA 108(22), 9250-55.

Contact Details: Chris Hebel
LC Sciences LLC
2575 West Bellfort St, Ste 270
Houston, TX 77054
713-664-7087
FAX 713-664-8181
chebel@lcsciences.com
www.lcsciences.com
chebel@lcsciences.com

 

This Sunday will mark the 30th anniversary of the first reports of AIDS in the United States

Jun 06 2011 /RTPR/ – This Sunday will mark the 30th anniversary of the first reports of AIDS in the United States. There is still a long road ahead toward eradicating HIV, but a “dream team for HIV reservoirs cure” has been created since 2003 with this objective.

While the HIV pandemic is still growing, with more than 7,100 daily new cases of infection, there is evidence that antiretroviral therapy costs could treble over the next 20 years.

Today there are more than 30 drugs approved to treat HIV, and while they cannot cure it, they can keep the virus suppressed to undetectable levels in blood. But HIV persists dormant in some “reservoir” and each time antiretroviral therapy is stopped, the infection rekindles. Lifelong therapy is therefore mandatory but brings problems of compliance, resistance, toxicity and cost.

These reservoirs were first described in 1997 and 5 years later Alain Lafeuillade, a French Doctor involved in HIV research, considered that it would be the challenge of the 21st Century. He consequently founded a working group uniting researchers from all over the world that first met in December 2003. This first “HIV Reservoirs, Persistence and Eradication Strategies Workshop” welcomed around 130 scientists actively involved in the field. “At that time we were seen as utopists, Doctor Lafeuillade said, and quite ignored by funding agencies and pharmaceutical companies”.

But minds greatly changed in the following years and in 2009, when the “dream team” met for the 4th time, the workshop was officially supported by the NIH (National Institutes of Health) and the ANRS (French Agency for AIDS Research). In between 2 workshops, the group of scientists are in touch via a specialized website portal they also have created.

“At the end of this year we will reconvene, Doctor Lafeuillade added, and be more than 200 scientists working on HIV cure”. The program of this 5th workshop goes from in vitro models of HIV persistence to HIV eradication clinical trials. “Participants will be able to define a clear road map for HIV cure research with a precise agenda”, Doctor Lafeuillade emphasized.

About the “HIV Reservoirs, Persistence and Eradication Strategies Workshop” Committees: founding fathers are Alain Lafeuillade (France), Mario Stevenson (USA), Robert Gallo (USA), Jose Gatell (Spain) and Christine Rouzioux (France). The scientific board contains David Margolis (USA), Jose Alcami (Spain), Tae-Wook Chun (USA), Mark Wainberg (Canada), Nicolas Chomont (USA), Monsef Benkirane (France), Françoise Barre-Sinoussi (France), Marie-Lise Gougeon (France)… Web site:http://www.informedhorizons.com/persistence2011/index.html

Contact: Alain Lafeuillade, informed Horizons, LLC
1860 Montreal Road, Suite 2, Tucker GA 30084 USA
Tel: +1 770 573 3020 | Fax: +1 866 534 6438
E-mail: kmorris@informedhorizons.com
Web site: http://www.informedhorizons.com/persistence2011/index.html

Advanced Cell Technology has pioneered a solution to the ethical, moral & legal debate raging in regards to protection of a human embryo

May 10, 2011 /RTPR/– Advanced Cell Technology with laboratory facilities in Marlborough Massachusetts has pioneered a solution to the ethical, moral & legal debate raging in regards to protection of a human embryo. ACT has developed the “single-blastomere” technique. Patent Number 7,893,315 a non-destructive alternative for deriving human embryonic stem cell (hESC) lines.

This achievement in Regenerative medicine is a ground breaking feat for both Catholic and U.S. law.

• The 1995 encyclical The Gospel of Life, of which Pope John Paul II wrote: “Human embryos obtained in vitro are human beings and are subjects with rights; their dignity and right to life must be respected from the first moment of their existence. It is immoral to produce human embryos destined to be exploited as disposable ‘biological material'” (1,5 )
• The Dickey Amendment (also known as the Dickey-Wicker Amendment) is the name of an appropriation bill rider attached to a bill passed by United States Congress in 1995, and signed by former President Bill Clinton, which prohibits the Department of Health and Human Services (HHS) from using appropriated funds for the creation of human embryos for research purposes or for research in which human embryos are destroyed.

The single-blastomere technology uses a one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential. The stem cells generated using this approach are healthy, completely normal, and differentiate into all the cell types of the human The safety record for one-cell biopsy as part of PGD now has a 15-year track record, and is carried out routinely as part of IVF processes around the world. ACT’s technique of protecting the human embryo from harm can be expounded to the smallest blood transfusion in the world. As does a human being give millions of blood cells in a pint of blood so does ACT’s “single blastomere” process take but “one cell” from a 2 day old embryo. As the blood removed from a human donor “regenerate” the removed pint of blood so does the human embryo “regenerate” the one cell. Both of these procedures leave the human body & two day old embryo healthy. Both procedures are similar in that they both provide life saving material to those whom need them most to due to disease and other aliments of a medical nature.

Advanced Cell Technology has been granted by the US Food and Drug Administration (FDA) a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells for both Stargardt’s Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world and Dry Age-Related Macular Degeneration (AMD) the most common form of macular degeneration in the world affecting an estimated 150 million people. ACT is using RPE cells developed from the patented (SCB) technique for this trial. The trial will take place at UCLA’s Jules Stein Eye Institute in California. Because of the biological nature of the human eye the trial will be able to provide a 100% irrefutable proof that the (hESC) derived RPE cells used attached to the Bruch’s membrane. Before and after state of the art imaging will take place.

Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world’s foremost experts in retinal cell physiology and vision restoration, commented, “The study results of ACT’s RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run.”

FDA validation will occur for (hESC) medicine in less than 12 months. Will those that dictate law and morality to others lead? Will those suffering from disease all over the world finally have conclusive proof that (hESC) work? Life is filled with multifaceted choices and in a rare occurrence a quantum leap shows itself to the world. Human flight, computers and now regenerative medicine.

Disclosure: Stem Cell Media LLC nor its Companies was compensated by “any” entity for this article.www.investorstemcell.com is bringing investors and stakeholders together to participate in the world’s only online discussion forum dedicated to regenerative medicine.

Contact Details: icell@investorstemcell.com
www.investorstemcell.com

###

NASDAQ:GERN & OTC:ACTC – A David & Goliath Comparison

May 09, 2011 /RTPR/– Regenerative medicine is a highly complicated and vastly misunderstood science. Investor Stem Cell is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements unfolding in the regenerative medicine sector. A quantum leap in health care is upon the world. Will you profit from this emerging sector & help bring cures to millions? Find out now what the street thinks at www.investorstemcell.com.

Side by side comparison of Advanced Cell Technology & Geron Corporation:

Geron Corporation (NASDAQ:GERN), Approved by the FDA to use human embryonic stem cell (hESC) treatments to treat spinal cord injuries. The research Goliath is a well-funded machine employing the top minds in the world working on everything from mid-stage oncology trials to promising (hESC) drugs for spinal cord injuries, heart disease & cancer.

Snap shot of Goliath: Geron Corpoartion-(NASDAQ:GERN)-
• Seven oncology Phase 2 trials currently underway, and has several big Pharma joint venture agreements in oncology animal and human trials
• Five hESC areas of investigation underway. GRNOPC1 is the lead candidate. Geron destroys the human embryo through its (hESC) R&D, of which the company uses the blastocyst embryo formation at day five after fertilization from IVF clinics
• Cash, restricted cash, cash equivalents and marketable securities: $221,274.000.00
• Total operating expenses in 2010: $114,730,000.00
• 175 employees; over 100 hold PhD or MD degrees
• Geron Corporation was founded in 1990 and is based in Menlo Park, California
• Trades on the NASDAQ providing liquidity & large institutional investors
• Corporate financial statements:http://www.geron.com/investors/reports/GeronAnnualReport2010.pdf

Advanced Cell Technology not too long ago was the predominant leader in the field of regenerative medicine. It fell from that distinction in part due to executive management hubris and ultimately the credit crisis in mid-2008. ACT was able to resurrect itself from near bankruptcy in June 2008 and now has the distinction of holding two out of the three FDA approved (hESC) trials. ACT is led by a competent executive management team and employs several of the most predominant regenerative researcher(s) in the world.

Snap shot of David: Advanced Cell Technology-(OTC:ACTC)-
• Retinal Pigment Epithelial Cell Program is their lead program-(HESC) trials for both SMD/AMD are expected to start in week(s) Jules Stein Eye Institute at the University of California, Los Angeles (UCLA ) will conduct the 2 (hESC) trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD)
• Filed a European Clinical Trial Application for Phase 1/2 study using (hESC) to treat macular degeneration
• Issued a broad patent for hESC-derived RPE cells in China
• Seeking funding & joint venture partner for Myoblast program for the treatment of cardiovascular disease Phase 2 approved by the FDA
• Joint ventured with Korean medical giant CHA to form “Stem Cell & Regenerative Medicine International” (SCRMI). This partnership expected to file an investigational new drug application (IND) with the FDA in Q-4 of this year. CHA biotech is waiting for final approval from the Korea Food and Drug Administration for (hESC) trial for AMD
• Issued patent on its “single-blastomere” technique. Patent Number 7,893,315 broadly covers ACT’s proprietary single-blastomere technology that provides a non-destructive alternative for deriving hESC lines. This “Embryo-Safe” one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential
• 22 full-time employees, six hold PhD or MD degrees-Formed in 1994, HQ in Menlo Park, California with laboratory facilities in Marlborough, MA
• Total operating expenses in 2010: $22,044,701
• Cash, restricted cash, cash equivalents and marketable securities: $34,889,409
• Trades on the OTC:BB ACTC is a Sarbanes–Oxley Act SEC reporter
• Corporate financial statements:http://www.sec.gov/Archives/edgar/data/1140098/000101376211000631/form10k.htm

If you are looking for maximum possible ROI in the short term and can tolerate high risk, then maybe Advanced Cell Technology (OTC:ACTC) is for you? If ACT is validated by the FDA, the (RPE) MA-09 “embryo-safe” cell lines would open up an annual $25,000,000,000.00 market treating (AMD). Yes that is (b) with an (illion) annual market share! No FDA approved treatment exist for (AMD) in the world. This disease effects 30 million in the USA & EU alone. Cell lines have potential to treat 200 retinal eye diseases. ACT has been approved for U.S. Orphan Drug status protection for (SMD). This status by the FDA provides ACT seven years of market protection. ACT is expecting EU-Orphan Drug status for (SMD) and if awarded would receive 10-years of market protection. The recent patent protection for ACT’s RPE cells in China firmly establish potential world dominance of the (AMD) market. What is the down side? One glaring red flag is that ACT has two years of operating capital and enough cash to fund both the SMD/AMD Phase-1/2 trials in the U.S. If ACT’s AMD/SMD trials are not validated, ACT would most likely be forced to institute a massive reverse split due to the O/S nearing its A/S. ACT has placed all of its eggs in one pipeline basket, choosing the low hanging fruit model. ACT is counting on the exceptional Casey Eye Clinic animal results. Dr. Raymond Lund Ph.D., considered one of the world’s foremost experts in retinal cell physiology and vision restoration. Dr. Lund recently said the following: “The study results of ACT’s RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run.”

Disclosure: www.investorstemcell.com is the world’s only online discussion forum dedicated bringing investors & stakeholders together in thoughtful discussion about stem cell & regenerative medicine. www.investorstemcell.com nor any of its Companies have been compensated by “any” party for this article. Before making an investment decision an investor should perform due diligences. Once completed find out what the street thinks at www.investorstemcell.com

Contact Details: www.investorstemcell.com
icell@investorstemcell.com

###

Investor Stem Cell Launches Online Discussion Community Dedicated To Stem Cell Investors

APR 29, 2011 /RTPR/ — Investor Stem Cell (http://www.investorstemcell.com) is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible medical advancements taking place in the regenerative medicine sector. Scientists are using stem cells both (hESC) and (iPSC) in hopes of easing the suffering of hundreds of millions of people world wide.

Our society is on the verge of a quantum leap moment in time thanks to regenerative medicine.

Regenerative medicine and Stem Cell research:

Utter those words at your next dinner party or casual gathering of friends and family. You will receive a concoction of half-truth’s and out right fallacy responses. Stem Cell research conjures images of futuristic Star–Trek like preservation chambers, human looking ears protruding oddly from the backs of mice, or worse yet an image of a late term fetus. Nothing could be farther from the truth when entering the reality of Regenerative medicine.

Never before has this area of research been more exciting and promising than right now. There is a medical revolution brewing, and like any revolution, there are those who want to suppress this uprising for continued personal and ideological gains. If we were to take all the major advances in the past 500 years of human medical history and multiply its effect by 10 fold it still would not compare to the paradigm shift in health care delivery that the world may witness in this decade using stem cells. Imagine that an $800,000 heart transplant is no longer needed and that instead the same money spent on one patient can now be stretched out to treat 20 patients who are needing a heart transplant. Is this what Regenerative medicine has in the offing? Only time will tell. Our healthcare system could very well be on the verge of a quantum leap moment thanks to regenerative medicine.

The Food and Drug Administration (FDA) authorized 3 trials using human embryonic stem cells (hESC) in late 2010. Validation of hESC research efforts and the culmination of billions spent on research are coming to fruition. FDA validation for the treatments of spinal cord injury and age related macular degeneration is expected in 2011. It may be the shot heard around the world event sometime in late Q-4 2011 for the Regenerative medicine sector.

Find out more at http://www.investorstemcell.com, where investing is much more than charts and numbers.

Investor Stem Cell offers dedicated forums to the following Stem Cell Companies.
Investor Stem Cell is free to all members and employs the state of the art discussion web based software to maximize the experience of its members and the user experience. Get involved now and start separating fact from fiction in Regeneration medicine.

Investor Stem Cell provides Forums for the below Stem Cell Companies.

Advanced Cell Technology (OTC:ACTC) Geron Corporation (NASDAQ:GERN)

Cord Blood America (Public, OTC:CBAI) BioTime (AMEX:BTX)

Aastrom Biosciences (NASDAQ:ASTM) Athersys Inc. (NASDAQ:ATHX)

International Stem Cell Corporation (OTC:ISCO) MultiCell (OTC:MCET)

StemCells, Inc. (NASDAQ:STEM) Thermogenesis (NASDAQ:KOOL)

Bioheart Inc. (OTC:BHRT) RTI Biologics (NASDAQ:RTIX)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Bio-Matrix Scientific Group (PINK:BMSN)

Neuralstem (AMEX:NBS) Opexa Therapeutics (NASDAQ:OPXA)

Stem Cell Authority (PINK:SCLL) Brainstorm Cell Therapeutics (OTC:BCLI)

Stem Cell Therapeuitics (CVE:SSS) Cyro-Cell International (OTC:CCEL)

CellCyte Genetics(OTC:CCYG) Stem Cell Innovations (PINK:SCLL)

BioMimetic Therapeutics (NASDAQ:BMTI) Mesoblast (ASX:MSB)

Cytori Therapeutics (NASDAQ:CYTX) SANUWAVE Health, Inc. (OTC:SNWV)

Disclosure: By being a visitor and or member of Investor Stem Cell you agree to adhere to the Terms of Service at all times & pay strict attention to (TOS) Stem Cell Media LLC – http://www.investorstemcell.com is not paid by any 3rd party now or in the future to promote “any” companies for credibility and ethical reasons. Investors Stem Cell is not a financial advisory service. Consult your financial advisor at all times before making an investment. Our society is on the verge of a quantum leap moment in time thanks to regenerative medicine.

Contact Details: www.investorstemcell.com
email = icell@investorstemcell.com

###

Sky Reading At Your Finger Tips With VB Sky Reading Experts

February 21, 2011 – If you are looking for the answer to all the questions about the mysteries of life, you can use the universal powers of Sky Reading to get all the answers whenever you want. The team of expert professionals at VB Sky Reading has made a name for themselves through the countless feedback from people whose queries have been satisfactorily answered. Similar sentiments can be seen in the words of the official spokesperson when he comments “We receive queries on a regular basis as more and more people opt to unlock new secrets about themselves and their lives through such readings.”

The spokesperson talks about the nature of the questions themselves as he says “Many come to our psychic reading sessions to inquire about the state of their education, health or even marriage prospects in the future. We deal with love and relationship problems so you can know more about prospective partners for you and your loved ones. Our psychic reading experts can also give you a glimpse of who you were in your past life along with several interesting predictions about the past, present and future. All of your questions can help you discover the hidden secrets and decipher them much ahead of time.”

Speaking about the exclusive advantages, the spokesperson says “Here at VB Sky Reading, we take pride in the practice of the ancient art that has been carefully carried down through centuries. We just ask you a few simple questions and use them as the platform for further analysis. You might know extremely little about your own inner self but we can provide a descriptive analysis in our sessions. You can learn about your strengths and weaknesses that can completely change the course of your life. All of this is done at extremely affordable rates so you do not have any sort of financial concerns.” He ends the keynote as he says “To know more about how our sessions can transform you as a person, visit our website at http://www.thevbskyreading.org and use Sky Reading to recreate your happiness.”

Contact Details:

TheVbSkyReading.org

1274 49 St. #266

Brooklyn, 11219

Phone Number : 347-526-0231

Email: thevbskyreading@thevbskyreading.org

Watchers of the Rainbow Covenant – New Sci-Fi Thriller-Mystery Novel

New Author Derrick G. Lindsey’s novel Watchers of the Rainbow Covenant confronts paranormal phenomena and science with Biblical scripture. One of the great anomalies of our modern time, is that atheists attack the Bible as being full of “ignorance” and a tool written by ignorant men “to enslave” those who believe. This could not be further from the truth. Even if you don’t believe in divine inspiration, the writers were the greatest minds of their time. The greatest philosophers, statesmen, planners, organizers, military leaders, and “yes” even scientist of their day. Theirs was cutting edge thinking in a constantly changing world of demagogies, wars, famines, and new scientific discoveries. Much like the world we live in today.

Derrick G. Lindsey explodes onto the literary scene with a compelling, fast paced and suspenseful novel set in a dynamic future. What is truly fascinating is how it confronts cutting edge theories of today on the creation of the universe with the Biblical accounts of creation.

The story is a step by step mystery that evolves, but the science is what is ground breaking. A true fusion of the two trains of thought (Religion and Science) which actually are very complementary to each other.

Paranormal phenomena folklore dating back thousands of years, and presented in theories and in the media today are brought face to face with the ageless text of the Bible.

Watchers of the Rainbow Covenant is a joy ride on a fast plane into a world 200 years from today. One need not be a Biblical scholar or a science fan of the latest theories to enjoy it. One merely has to love science fiction and you will love this novel.

About the Author:
Derrick G. Lindsey is a Computer Science Engineer who has worked for various NASA projects in his career, most notably the U.S. Space Shuttle.

He has studied at Fuller Theological Seminary Pasadena California, and The Kings Seminary in Van Nuys California where he is pursuing a Masters of Divinity Degree.

Media Contact:

Derrick G. Lindsey
Email: DGLINDSE@PACBELL.NET

Phone (818) 470- 5868

Video Trailer “Watchers of The Rainbow Covenant” at http://www.youtube.com/watch?v=UJUz3UxMLgk

Published through Xulon Press 12/21/2010, Watchers of The Rainbow Covenant is available via the Xulon Press Online Bookstore, Amazon, Barnes and Noble, and various other online Bookstores,

Contact Details: 17371 Raymer St., Northridge Ca. 91325
818-470-5868
DGLINDSE@PACBELL.NET

ChiroSolve, Inc. Launches New Method Development Kits

Santa Clara, CA. – February 4, 2011- CHIROSOLVE INC., continues to enhance the world of enantiomeric separation with the introduction of two new customer-centric packaged solutions, EnantioPrep and ScalePrep, that are intended for high efficiency chiral separation of enantiomers. They offer seamless transition from identification of initial separation conditions to fully optimized method development within a matter of days.

ChiroSolve has been very successful in producing a line of chiral kits tailor made for scientists at different stages of their research. EnantioPrep includes a set of ChiroSolv™ kits to be used in a simple 3-step process. The kits employ ChiroSolve’s patented approach to comprehensively screen 384 separation conditions providing the knowhow for a successful outcome. The use of this package results in the identification of a complete step by step, time, cost and resource efficient procedure and an enantiopure compound. This product is especially useful for scientists in the early stages of drug discovery.  ScalePrep is targeted at those scientists looking to produce larger amounts of pure product with the identification of an ideal production route that can be scaled up to provide kilo quantities of highest enantiomeric purity. ChiroSolve also offers a set of relevant services to complement these products.

The company has recently developed a fully automated system to handle this entire process from the initial screening to finding the optimal synthetic route. If you are interested in being among the first of many to gain access to this new technology, contact ChiroSolve at info@chirosolve.com or call us at (408) 834-8597. You can learn more about ChiroSolve and its products and services at the company’s website: www.chirosolve.com.

Molplex and Enamine Announce a New Partnership

Newcastle, UK and Kiev, Ukraine. January 24th 2010 – Molplex and Enamine today announced a new partnership to offer the Enamine screening collection of 1.8 million stock chemicals through the Molplex online drug design and assay-ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs ofdrug discovery, bringing sophisticated drug design, compound management and assay-ready chemistry to the world’s drug discovery scientists on demand. The agreement adds Molplex online drug design systems to the deep experience in organic chemistry and compound management of Enamine to solve the problem of generating viable chemical leads for novel targets.

Molplex CEO David E. Leahy said: “We are very proud to be selected by Enamine as their partner for on demand drug discovery services at a time when major restructuring of the industry is creating new opportunities and new markets for our combined expertise. This agreement marks a step change in the size and scope of our assay-ready chemical supply service and major progress towards our goal of being the world’s first choice partner for enabling the long tail of drug discovery”

Enamine Chief Marketing and Sales Officer Dr Vladimir Ivanov said “We are happy to partner with Molplex and supply our products to the highly integrated drug discovery platform they maintain. In this collaboration we deploy all our discovery resources including the world’s biggest screening collection (1.8 million compounds), largest inventory of building blocks (45,000 products), and over 300 chemists at our Kiev’s site to assure high cost efficiency and high responsiveness to any follow up chemistry emerging from projects run through Molplex discovery platform.”

About Molplex
Molplex was created by David Leahy and Vladimir Sykora to help anyone anywhere in the world invent new medicines. Molplex’s ambition is to eliminate the high set up costs of drug discovery providing the sophisticated online drug design systems integrated with assay ready chemical supply and high content screening. CEO David Leahy previously founded Cyprotex PLC, now the world’s largest ADME Tox service supplier. The Molplex team offers extensive drug discovery experience and sophisticated software systems for automated drug design. Molplex goal is to enable the long tail of drug discovery to provide the new medicines of tomorrow by eliminating the cost of entry and increasing success rate of drug discovery projects

For more information visit www.molplex.com.

About Enamine
Enamine has been established as a provider of research services to the pharmaceutical and biotechnology industry since 1991 and is the world’s largest chemistry supplier of innovative compound libraries and building blocks to the pharmaceutical industry.

For more information on Enamine visit www.enamine.net

Contact Details:

David Leahy, CEO,
Molplex Ltd.
i6 Charlotte Square
Newcastle Upon Tyne
England, NE1 4XF
info@molplex.com
Tel: US: 1-408-905-2900
Europe : 44-191-211-196
Dr Vladimir Ivanov, Chief Marketing and Sales Officer
ENAMINE Ltd.
23 Alexandra Matrosova Street
01103 Kiev, Ukraine
v.ivanov@enamine.net
Tel: +38 044 537 32 18
Fax: +38 044 537 32 53

Gene Therapy and Stem Cell Therapy Standard Developed For A Unique Derivative Of Post Hetero-Plastic Inplantation Chronic Inflammation Syndrome

Researchers task force, led by faculties of T-Protocol, registered Genom Project as controlled genom project in the hosted database of NCBI, a publication matter authority and function assigned organization under oversee of Department of Health & Human Services, reached once to share the exegetical impression officially pre-published concerning the understanding specific spectrum of symptoms covering boroad range of character usually complained and observed through chronic inflammation, granuloma, some types of lymphoma and various uncommon symptoms to let physician scientists suspecting indicium of neurological diseases, NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and setting Massachusetts indications of treatments standardized manual (Massachusetts manual) & diagnostic and standardized medical treatment manual for post hetero-plastic inplantation chronic inflammation syndrome, specific edition against NIDO Disease.

The once defined causes of NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome are considered each of a common living organism to cause conformational diseases like Creutzfeldt-Jakob disease, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and kinds of and a set of biochemical and physical reaction and response realized by cross-species gene- mutation, as biotransformation, easily describing natural physiological and biochemical changes in vivo substrate of human bodies. After this studies, standardized protocol of gene therapy and applied stem cell therapy is now in practice and on available.

Faculties,committing themselves entirely to the project, of each institutes and organizations participating the project to ascertain proteins and DNA/genomic DNA/genom of human, other mammal and virulent microorganism including bacillus/virus affecting each symptom and the symptoms’ spectrum expressed generally and observed commonly on patients suffered from NIDO disease, extraordinarily unique derived type of post hetero-plastic implantation chronic inflammation syndrome and to develop diagnostic standard and treatment protocol standardized and to find a clue compose gene therapy protocol and applied stem cell therapy protocol to entirely heal NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and to let all of current suffered patients from various combined symptoms directly derived by chronic inflammation and various tumors, have to express full surprise at the fact that these disease and patients suffered are made up and left no attention and no relief.

Commissioner of ethics board of the project will agree that this case should be regarded as not agreed human experimentation.

Contact Details: Genom Project Matter: http://www.ncbi.nlm.nih.gov
T-Protocol Treatment Matter: medinfo@vistomail.com
or near RMP accredited issuing referral